Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis

Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, canagliflozin (CAN), improves myocardial perfusion to ischemic territory without accompanying changes in vascular density. We aimed to (1) characterize effects on angiogenic pathways, (2) utilize multiomics to identify gene expression and metabolite profiles relevant to regulation of myocardial blood flow, and (3) investigate drug effect on coronary microvascular reactivity.

Source: The Journal of Thoracic and Cardiovascular Surgery - August 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Debolina Banerjee, Sharif A. Sabe, Hang Xing, Cynthia Xu, Mohamed Sabra, Dwight D. Harris, Mark Broadwin, M. Ruhul Abid, Anny Usheva, Jun Feng, Frank W. Sellke Source Type: research